APPROLIX
ApProlix is a mobile innovative technologies company. The company was founded in 2008.
APPROLIX
Industry:
Cloud Computing Information Services Information Technology
Founded:
2008-09-01
Address:
Ramat Gan, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.approlix.com
Total Employee:
1+
Status:
Active
Contact:
+972-542-463-493
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API WordPress HSTS IPv6 Cloudflare Hosting Wordpress Plugins
Similar Organizations
Cloudatix
Cloudatix is an information technology and services company.
FusionData
FusionData is an information technology and services company.
Current Employees Featured
Founder
Official Site Inspections
http://www.approlix.com
- Host name: server.mangulator.com
- IP address: 103.204.128.231
- Location: Bangladesh
- Latitude: 23.7018
- Longitude: 90.3742
- Timezone: Asia/Dhaka
More informations about "ApProlix"
ApProlix - Crunchbase Company Profile & Funding
ApProlix is a mobile innovative technologies company. The company was founded in 2008.See details»
Clotting Factor IX for Hemophilia B | Alprolix.com
ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek …See details»
Approlix Company Profile | Management and Employees List
Approlix Profile and History. Approlix is a company that operates in the Consumer Electronics & Computers Retail industry. It employs 10to19 people and has 1Mto5M of revenue.See details»
Financial Support and Information | Alprolix.com
ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek …See details»
Health Canada Approves Marketing License Transfer for
Jul 10, 2017 ALPROLIX is manufactured using a human cell line in an environment free of animal and human additives. ... Organization Profile. Bioverativ Canada Inc. Contact Cision. …See details»
ALPROLIX®
ALPROLIX can affect fertility or sperm development in hemophilia B patients. No impact on male or female reproductive organs was shown in toxicology studies in rats and monkeys. Special …See details»
Hemophilia B coagulation Factor IX concentrate for adults and …
Switch to ALPROLIX ®, the first EHL with 10 years of experience across ages and settings 1-3. ALPROLIX® is a recombinant DNA derived, coagulation Factor IX concentrate indicated in …See details»
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …
Alprolix should be administered using an infusion set which may be provided with the drug product, and the prefilled diluent syringe provided. Reconstitute lyophilized Alprolix powder for …See details»
ALPROLIX | FDA - U.S. Food and Drug Administration
October 19, 2017 Summary Basis for Regulatory Action - ALPROLIX November 3, 2017 Approval Letter - ALPROLIX Approval History, Letters, Reviews, and Related Documents - ALPROLIXSee details»
How ALPROLIX ® works
ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek …See details»
COAGULATION PRODUCTS FOR HEMOPHILIA B
Alprolix Manufactured and distributed by Sanofi Genzyme Produced in a human embryonic kidney (HEK) cell line. Covalently linked to the Fc domain of recombinant human immunoglobuli n G1 …See details»
Frequently asked questions - ALPROLIX
ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek …See details»
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX
Mar 24, 2014 ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is the first long-acting fully recombinant clotting factor therapy. ... Organization Profile. Biogen Idec …See details»
ALPROLIX® [coagulation factor IX (recombinant), Fc fusion
ALPROLIX potency is assigned using a validated in vitro, activated partial thromboplastin time (aPTT)–based, one-stage clotting assay calibrated against the World Health Organization …See details»
Alprolix® (rFIXFc) approved in the EU for the treatment of ... - Sobi
May 13, 2016 Alprolix® is a recombinant clotting factor therapy developed for haemophilia B by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly …See details»
Connect with an Alprolix Specialist | Alprolix.com
ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek …See details»
ALPROLIX®
ALPROLIX has been evaluated in two open label studies (Study 1 and Study 2) which were . ALPROLIX Product Monograph Page 7 of 36 conducted in previously treated patients (PTPs) …See details»
Package Insert - ALPROLIX - U.S. Food and Drug Administration
ALPROLIX, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived coagulation Factor IX concentrate indicated in ... World Health Organization (WHO) …See details»
Evaluation of a Quantity Limit on Hemophilia Factor Products in a …
Evaluation of a Quantity Limit on Hemophilia Factor Products in a Large Managed Care Organization: Pharmacy Cost and Utilization Outcomes Raquel S. Erb, PharmD Candidate1,2; …See details»
ALPROLIX® Rx Only Coagulation Factor IX (Recombinant), Fc …
Administer ALPROLIX. ALPROLIX should be injected intravenously over several minutes. The rate of administration should be determined by your comfort level. The small amount of drug …See details»